Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 4/20 | 0.32 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26674831 | 0.84 | CA1 (0.36) | CA1CA2CA9MAPTADRB2 | |
| SCHEMBL21811398 | 0.82 | CA1 (0.39) | CA1CA2CA9MAPTGAA | |
| SCHEMBL4007556 | 0.78 | MAPT (0.43) | CA1CA2CA9MAPTGAA | |
| SCHEMBL23813836 | 0.78 | HDAC1 (0.35) | KDM1AKDM1BHDAC1HDAC6 | |
| SCHEMBL22118356 | 0.77 | CA1 (0.39) | CA1CA2CA9MAPTGAA | |
| SCHEMBL21729520 | 0.77 | POLB (0.34) | GAAADRB2 | |
| SCHEMBL11067091 | 0.76 | MAPT (0.42) | CA1CA2CA9MAPTGAA | |
| SCHEMBL11131454 | 0.76 | MAPT (0.42) | CA1CA2CA9MAPTGAA | |
| SCHEMBL19475196 | 0.76 | CA1 (0.42) | CA1CA2CA9MAPTGAA | |
| SCHEMBL29502108 | 0.76 | CA1 (0.42) | CA1CA2CA9MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115308-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | FORTVITA BIOLOGICS LTD (CN) | 2026-04-30 | — | — | US | disclosed |
| US-12521444-B2 | Anti-HER2 antibody-drug conjugates and uses thereof | FORTVITA BIOLOGICS LIMITED (CN) | 2026-01-13 | — | — | US | disclosed |
| EP-4559525-A2 | INHIBITING HUMAN INTEGRIN ALPHA4BETA7 | Morphic Therapeutic, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-4045039-B1 | INHIBITING HUMAN INTEGRIN ALPHA4BETA7 | MORPHIC THERAPEUTIC INC (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2025043225-A2 | DEGRADERS OF CYCLIN-DEPENDENT KINASE 2 | GENENTECH, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| US-20250000996-A1 | CAMPTOTHECIN DERIVATIVES AND CONJUGATES THEREOF | FORTVITA BIOLOGICS LIMITED (CN) | 2025-01-02 | — | — | US | disclosed |
| CN-119192137-A | Inhibition of human integrin alpha4β7 | 莫菲克医疗股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| US-12029736-B2 | Camptothecin derivatives and conjugates thereof | MEDIBOSTON LIMITED (HK) | 2024-07-09 | — | — | US | disclosed |
| US-12029736-B2 | Camptothecin derivatives and conjugates thereof | MEDIBOSTON LIMITED (HK) | 2024-07-09 | — | — | US | disclosed |
| US-12029736-B2 | Camptothecin derivatives and conjugates thereof | MEDIBOSTON LIMITED (HK) | 2024-07-09 | — | — | US | disclosed |
| EP-2280981-B1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2280981-A1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-02-09 | — | — | EP | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| WO-2009117540-A1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009117540-A1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250000996-A1 | CAMPTOTHECIN DERIVATIVES AND CONJUGATES THEREOF | TOP2A, TOP1, XPA | CA1 1954/4885CA2 4321/4885CA9 1053/4885 |
| US-12029736-B2 | Camptothecin derivatives and conjugates thereof | TOP2A, TOP1, XPA | CA1 1954/4885CA2 4321/4885CA9 1053/4885 |
| US-20260115308-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | ERBB2, FUT5, FUT6 | CA1 500/4885CA2 676/4885CA9 615/4885 |
| US-20090253677-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | CA1 4824/4885CA2 4114/4885CA9 3450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.